Open AccessHormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women
Author(s) -
David C. Grossman,
Susan J. Curry,
Douglas K Owens,
Michael J. Barry,
Karina W. Davidson,
Chyke A. Doubeni,
John W. Epling,
Alex R. Kemper,
Alex H. Krist,
Ann Kurth,
C. Seth Landefeld,
Carol M. Mangione,
Maureen G. Phipps,
Michael Silverstein,
Melissa A. Simon,
ChienWen Tseng
Publication year - 2017
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2017.18261
Subject(s) - medicine , menopause , hormone therapy , hormone replacement therapy (female to male) , dydrogesterone , estrogen , stroke (engine) , breast cancer , gynecology , cancer , testosterone (patch) , mechanical engineering , engineering
Menopause occurs at a median age of 51.3 years, and the average US woman who reaches menopause is expected to live another 30 years. The prevalence and incidence of most chronic conditions, such as coronary heart disease, dementia, stroke, fractures, and breast cancer, increase with age; however, the excess risk for these conditions that can be attributed to menopause alone is uncertain. Since the publication of findings from the Women's Health Initiative that hormone therapy use is associated with serious adverse health effects in postmenopausal women, use of menopausal hormone therapy has declined.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom